Joan's Legacy: Uniting Against Lung Cancer
27 Union Square West, Suite 304, New York, NY 10003 • ph: 212.627.5500 • fax: 212.627.7594
 
 

 

David N. Reisman, M.D., Ph.D., University of Michigan: Alteration in the SWI/SNF Chromatin Remodeling Complex in Bronchioalveolar Carcinoma

The long-term goal of our research is to develop treatments for bronchioloalveolar carcinoma (BAC) and other lung cancers. To understand how to cure these diseases, we need to understand their biology. BAC patients constitute about 5% of the total lung cancer patients in the U.S. today; thus relatively little research has been dedicated to the understanding of the biology of this cancer, and even less into finding a cure. In fact, researchers lack even basic research models and tools to study this disease. The goal of this proposal is to adapt our mouse model of lung cancer to study BAC and to gain insight into the biology of the disease by looking at two of the proteins we believe are involved. These proteins, BRM and BRG1, are part of a large protein complex, called SWI/SNF, which is known to be involved in regulating many cellular processes, including the growth of cells. Our research indicates that when SWI/SNF stops functioning, the cellular processes it regulates are drastically affected. In particular, cells can grow continuously in the absence of these regulatory proteins. Our laboratory has found that when the SWI/SNF components BRM and BRG1 stop functioning, they affect the ability of the regulatory protein Retinoid Acid Receptor (RAR) to do its work and stop excessive cell growth. Fortunately, we have also found that it is possible to restore the function of BRM. This suggests that BRM—and perhaps other components of SWI/SNF—could help slow, or stop, the growth of cancer-related cells, since restoring BRM’s function would also restore the function of RAR. To achieve this goal, we need to define exactly which components of SWI/SNF are affected in BAC and then determine how these alterations affect RAR. We will use two main approaches: first, we will identify specific genes involved in BAC, and second, we will induce lung cancer in our mouse model to see how RAR function is changed when BRM and other subunits are removed. We believe this research will benefit BAC patients, not only by providing a means of understanding the biology of this disease, but also by giving us important insight into possible treatments.

 

 
 
Joan's Legacy is a 501(c)(3) tax-exempt organization.